PMID- 29641741
OWN - NLM
STAT- MEDLINE
DCOM- 20180601
LR  - 20230423
IS  - 2359-4292 (Electronic)
IS  - 2359-3997 (Print)
IS  - 2359-3997 (Linking)
VI  - 62
IP  - 2
DP  - 2018 Mar-Apr
TI  - Short-term insulin intensive therapy decreases MCP-1 and NF-kappaB expression of 
      peripheral blood monocyte and the serum MCP-1 concentration in newlydiagnosed 
      type 2 diabetics.
PG  - 212-220
LID - S2359-39972018005001112 [pii]
LID - 10.20945/2359-3997000000029 [doi]
AB  - OBJECTIVE: To observe the effect of short-term insulin intensive treatment on the 
      monocyte chemoattractant protein-1 (MCP-1) as well as on the nuclear factor-kappa 
      B (NF-kappaB) expression of peripheral blood monocyte. This is also in addition to 
      observing the serum MCP-1 level in newlydiagnosed type 2 diabetic patients and 
      probing its anti-inflammation effects. SUBJECTS AND METHODS: Twenty 
      newly-diagnosed type 2 diabetic patients were treated with an insulin intensive 
      treatment for 2 weeks. MCP-1 and NF-kappaB expression on the monocyte surface were 
      measured with flow cytometry, the serum MCP-1 level was measured by enzyme linked 
      immunosorbent assay (ELISA) during pretreatment and post-treatment. RESULTS: 
      After 2 weeks of the treatment, MCP-1 and NF-kappaB protein expression of peripheral 
      blood monocyte and serum MCP-1 levels decreased significantly compared with those 
      of pre-treatment, which were (0.50 +/- 0.18)% vs (0.89 +/- 0.26)% (12.22 +/- 2.80)% vs 
      (15.53 +/- 2.49)% and (44.53 +/- 3.97) pg/mL vs (49.53 +/- 3.47) pg/mL, respectively (P 
      < 0.01). The MCP-1 expression on monocyte surface had a significant positive 
      relationship with serum MCP-1 levels (r = 0.47, P < 0.01). CONCLUSIONS: 
      Short-term insulin intensive therapy plays a role in alleviating the increased 
      inflammation reaction in type 2 diabetics.
FAU - Lin, Yang
AU  - Lin Y
AD  - School of Medicine, Shandong University, Jinan, Shandong 250100, China.
AD  - Department of Pediatrics, Anhui Provincial Hospital, Hefei, Anhui 230001, China.
FAU - Ye, Shandong
AU  - Ye S
AD  - School of Medicine, Shandong University, Jinan, Shandong 250100, China.
AD  - Department of Endocrinology, Anhui Provincial Hospital, Hefei, Anhui 230001, 
      China.
FAU - He, Yuanyuan
AU  - He Y
AD  - Department of Endocrinology, Anhui Provincial Hospital, Hefei, Anhui 230001, 
      China.
FAU - Li, Sumei
AU  - Li S
AD  - Department of Endocrinology, Anhui Provincial Hospital, Hefei, Anhui 230001, 
      China.
FAU - Chen, Yan
AU  - Chen Y
AD  - Endocrinological Laboratory, Anhui Provincial Hospital, Hefei, Anhui 230001, 
      China.
FAU - Zhai, Zhimin
AU  - Zhai Z
AD  - Department of Central lab, Anhui Provincial Hospital, Hefei, Anhui 230001, China.
LA  - eng
PT  - Journal Article
DEP - 20180405
PL  - Brazil
TA  - Arch Endocrinol Metab
JT  - Archives of endocrinology and metabolism
JID - 101652058
RN  - 0 (Chemokine CCL2)
RN  - 0 (Insulin)
RN  - 0 (NF-kappa B)
SB  - IM
MH  - Case-Control Studies
MH  - Chemokine CCL2/blood/*drug effects
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Inflammation/*prevention & control
MH  - Insulin/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Monocytes/*chemistry
MH  - NF-kappa B/blood/*drug effects
PMC - PMC10118989
COIS- Disclosure: no potential conflict of interest relevant to this article was 
      reported.
EDAT- 2018/04/12 06:00
MHDA- 2018/06/02 06:00
PMCR- 2018/03/23
CRDT- 2018/04/12 06:00
PHST- 2017/01/10 00:00 [received]
PHST- 2017/12/13 00:00 [accepted]
PHST- 2018/04/12 06:00 [entrez]
PHST- 2018/04/12 06:00 [pubmed]
PHST- 2018/06/02 06:00 [medline]
PHST- 2018/03/23 00:00 [pmc-release]
AID - S2359-39972018005001112 [pii]
AID - 2359-3997000000029 [pii]
AID - 10.20945/2359-3997000000029 [doi]
PST - epublish
SO  - Arch Endocrinol Metab. 2018 Apr 5;62(2):212-220. doi: 
      10.20945/2359-3997000000029. Print 2018 Mar-Apr.